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relationship between hepatitis C viral kinetics and IL28B
genotypes among Taiwanese CHC patients.
Methods: We enrolled 145 consecutive Taiwanese CHC
patients with pegylated interferon alfa-2a (Peg-IFN) plus
ribavirin for the study. Blood samples were taken more
frequently at deﬁned intervals in the ﬁrst 3 days. Pegylated
interferon alfa-2a (Peg-IFN) was administered weekly
together with daily ribavirin for 24 or 48 weeks according
to HCV genotypes. A new mathematical model was ﬁtted to
the observed HCV kinetics. In addition, the genomic DNAs of
91 patients who agreed to attend the host genomic survey
were obtained.
Results: A new mathematical model ﬁtted to the observed
HCV kinetics which could interpret the transient HCV titer
elevation after Peg-IFN treatment was constructed. The
results demonstrated a comparable viral clearance rate
(c = 3.45±3.73) (day 1, mean±SD) but lower daily viral
production rate (p = 106 1012) in our patients than that
reported before in Western patients. Of 110 patients with
sustained virologic response (SVR), 47 (43%) had a transient
elevation of viral titer within 12 hours (proportion of
12hours/3days, 44% in Non-SVR vs. 70% in SVR, p = 0.029).
Among 91 patients with available rs8099917 data, patients
with TT genotype had an early surge of viral titer after
therapy, higher SVR and viral clearance rate than those
with GT genotype.
Conclusions: Taiwanese CHC patients on Peg-IFN plus
ribavirin therapy have a lower daily viral production rate
than Western patients, and the rs8099917 TT genotype may
contribute to the increased viral clearance rate and better
virologic responses in these patients.
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CS3.1 Epidemiology and outcome of Candida
bloodstream infection in an intensive care unit in
Hong Kong
M. Hui *. Department of Microbiology, The Chinese
University of Hong Kong, Hong Kong, China
Candida albicans and Candida non-albicans are commonly
found as commensals in human body. However, they
are capable of producing life-threatening blood stream
infections. A retrospective review was undertaken to
analyze the characteristics of such infections in a single
centre intensive care unit. Emphasis was placed on
the demographics, risk factors, clinical manifestations,
complications as well as clinical outcome. In addition, the
distribution trend of different species of Candida was also
analyzed.
Our results revealed a high point prevalence of
candidaemia, and high crude mortality rate. Candida
albicans constituted half of all the cases, followed
by Candida tropicalis, Candida parapsilosis and Candida
glabrata. Age group analysis suggested that Candida
tropicalis outnumbered the other species in 10 19 years
old age group. An increasing trend of Candida glabrata was
observed with increasing age.
Our results suggested that early empirical antifungal should
be considered in high risk patients. The choice of antifungal
agents should cover the most likely Candida organisms in
the relevant age groups.
CS3.2 Efﬁcacy of common antifungal drugs
R.Y. Li *. Peking University First Hospital and Research
Center for Medical Mycology, Beijing, China
Abstract not available
CS3.3 Recent advances in management of cryptococcal
meningitis
T.C. Sorrell *. Sydney Institute for Emerging Infectious
Diseases and Biosecurity and Centre for Infectious Diseases
and Microbiology, Sydney Medical School Foundation
Fellow, Sydney Medical School, University of Sydney,
Westmead, Australia
Recent studies continue to highlight that there are
signiﬁcant clinical differences between infection due to
Cryptococcus neoformans and that due to its sibling species,
Cryptococcus gattii. There are emerging data suggesting
that molecular genetic types within each of the species
may also have different clinical presentations. Other species
dependent-differences include ecology, epidemiology and
host immune status. Neurological disease carries the highest
morbidity and mortality. Cryptococcal meningitis remains
a substantial health burden particularly in developing
countries, where it is associated with HIV infection
primarily. The major determinants of outcome include
neurological status, the level of intracranial pressure, the
presence of cerebral mass lesions and the cryptococcal load
in the CSF at presentation.
Antifungal treatment regimens should be guided by
host factors, severity of illness (including presence of
complications) and the causative cryptococcal species.
Recent clinical studies indicate the need for rapidly
fungicidal induction therapy regimens using amphotericin
B in combination with ﬂucytosine, to achieve optimal
outcomes. Maintenance therapy with ﬂuconazole is
necessary to prevent relapse and in the case of HIV
infection, until recovery of immune function. Cryptococcus
gattii meningitis requires prolonged induction/eradication
therapy. It is particularly important that prompt control of
raised intracranial pressure or hydrocephalus be achieved.
Clinicians should be vigilant for immune restoration like
features. Adjunctive surgery or corticosteroids may be
required to treat patients with large cryptococcomas,
cerebral oedema, or refractory infection.
The clinical relevance of isolates with relatively increased
minimum inhibitory concentrations of ﬂuconazole, that
have been observed in some small series of Cryptococcus
gattii infection, remains to be determined. Isolates of
Cryptococcus neoformans have remained susceptible to
ﬂuconazole, except where there has been widespread use
of ﬂuconazole as initial therapy for cryptococcal meningitis
in association with HIV.
CS3.4 Invasive fungal infections: Diagnosis and
treatments in China
Y.P. Ran*. Department of Dermatology, West China
Hospital, Sichuan University, China
The body location and clinical appearance of fungal
infections depends on the fungal virulence, infectious route
and host immunological state. The result being that patients
with mycoses consult with different clinical departments.
The diagnosis of mycoses is based on the detection of
fungal elements such as hyphae and/or yeast cells from the
involved tissues. Isolation of the fungus is the precondition
for species identiﬁcation and antifungal treatment. To think
clinically and to emphasize the mycology is the basic
consideration of medical mycology research. Working in
frontier of Translational Mycology, medical mycologists play
a key role in the collaboration between the aspects of
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clinical (bedside) and laboratory (bench). The clinician
always wants to know what the fungus is and how to
treatment the mycosis. Fungal pathogens are often stealthy
and difﬁcult to detect in infected patients during the early
stages of the diseases and this is when therapies would be
the most effective. Routine techniques commonly employed
in the detection of fungal diseases including microscopic
examination, culturing and serology are seriously hampered
by lengthy waits of times for results and low accuracy. The
clinician may want prophylaxis or to use empirical antifungal
treatment to see if it does/does not work. The problem is
that some of the patients do not respond to the antifungal
treatment, because the doctor lacked sufﬁcient evidence of
fungus infection to give the doctor conﬁdence to continue
treatment. Accurate and early diagnosis of fungal diseases
is critical for managing mycotic diseases. Our experience is
before starting antifungal treatment, we need to be sure
the tissue was invaded by a fungus. This is usually done by
direct microscopic examination (DME) of KOH preparations.
Good specimens are the key point that directly affects
the quality of microscopic evidence and culture. The most
important aspect is culturing samples on different media
with or without chloramphenicol and cycloheximide and
incubated at room temperature and 37ºC. PCR-based no-
culture methods are necessary in the cases of culture
negative, morphologic identiﬁcation not success, and, to
prove the species identiﬁed by routine. Early treatment
could save a patient’s life. We start treatment at the time
we have the proof of fungal infection, i.e., KOH positive.
Itraconazole, ﬂuconazole, terbinaﬁne, amphotericin B or its
liposome form, can be used alone or in combination based
on the fungal species involved and the site of infection.
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Scheme for diagnosis and treatment of invasive fungal infections.
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SOTA2 Highlights of the APASL Single Topic on HCV in
Chiba
M. Omata*. Yamanashi Central Hospital and University of
Tokyo, Japan
The diagnosis and treatment of HCV (Hepatitis C Virus) has
been changing drastically for the last 20 years. Therefore,
we feel the need to revise the guidelines maybe every 2 to
3 years to update the knowledge for clinical use.
The last publication on HCV guideline was 1992 by Dr. Geoff
McCaugh and and myself with 17 co-authors. However after
that, there is remarkable progress in understanding of the
pathogenesis and natural courses of HCV infection. For
example, the discovery of IL28b SNP revolutionized and
changed interferon treatment indications.
Recently, the SNP analysis chronicle HCV infection was
performed on large scale matters in Japanese patients,
and it was revealed several signiﬁcant SNPs were identiﬁed
to inﬂuence on the natural courses of the hepatitis virus
infection. Furthermore, the remarkable effort to develop
the innovative drugs for the treatment and cure of HCV
infection has been conducted for the last 10 years, and new
Protease Inhibitors will be on the market shortly. These new
drugs may change the paradigm of the treatment of HCV
infections totally, and we are now in vision even the total
cure of the diseases. Therefore, we are now in process to
revise APASL guidelines to be able to catch up the incredible
progress of the management on HCV infections.
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CS4.1 Personalized medicine for HCV treatment
M.-L. Yu*. Department of Internal Medicine, Kaohsiung
Municipal Ta-Tung Hospital, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan
Personalized therapy based on current standard of care,
pegylated interferon-a (PegIFN) plus ribavirin (RBV), has
become the mainstay for treatment of chronic hepatitis C
virus (HCV).
Genotype-guided therapy, based on HCV genotype,
recommended a 48-week regimen of PegIFN plus weight-
based RBV (1000 1200mg/d) for HCV genotype 1 or 4
(HCV-1/4); and a 24-week regimen of PegIFN plus ﬁxed,
low dose of RBV (800 mg/d) for HCV-2/3 infection.
The sustained virological response (SVR, serum HCV RNA
<50 IU/ml throughout 6 months of post-treatment follow-up
period) rate is around 50% and 83% for HCV-1/4 patients and
HCV-2/3 patients, respectively in Caucasian; and 70 75% and
85 90% in Asian patients, respectively. The optimal regimens
for HCV-5 or 6 remain to be determined.
Recently, response-guided therapy, based on on-treatment
virological responses, has become the new era of care. A
shorter 24-week regimen for HCV-1 with lower baseline viral
loads and a rapid virological response (RVR, serum HCV RNA
<50 IU/ml at 4 weeks of treatment) and an abbreviated 16-
week regimen with weight-based, standard dose of RBV for
HCV-2/3 could provide equal efﬁcacy to genotype-guided
SOC. By contrast, treatment should be stopped for HCV-1
patients without an early virological response (EVR, serum
HCV RNA <50 IU/ml or a 2 logs decline of HCV RNA from
baseline after 12 weeks of therapy). Furthermore, EVR has
been suggested to be subdivided into RVR, complete EVR
(no RVR, but HCV RNA <50 IU/ml at week 12) and partial
EVR (HCV RNA >2 log drop in HCV RNA but still detectable at
week 12) to further improve the prediction of patients who
are likely to achieve an SVR and may allow for extending
treatment duration to 72 weeks, especially for those of slow
responders.
More recently, the development of direct antiviral agents
(DAA, formally named speciﬁcally targeted antiviral therapy
for HCV, STAT-C) is ongoing. DAA has increased the number
